000250.KQ
Sam Chun Dang Pharm. Co., Ltd
KOE · Healthcare · Medical - Pharmaceuticals · KR
KRW 155,400.00
−2.26%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 259.9B | 231.8B | 210.9B | 192.7B | 177.3B |
| Cost of Revenue | 140.0B | 126.1B | 111.3B | 95.7B | 89.4B |
| Gross Profit | 119.9B | 105.7B | 99.7B | 97.0B | 87.9B |
| Operating Expenses | |||||
| R&D Expense | 7.0B | 8.5B | 7.8B | 5.0B | 5.5B |
| SG&A Expense | 70.7B | 58.3B | 56.8B | 52.0B | 68.4B |
| General & Admin Expense | 9.7B | 12.0B | 11.7B | 11.4B | 9.9B |
| Selling & Marketing Expense | 35.9B | 46.3B | 45.1B | 40.6B | 35.2B |
| Other Expenses | 26.3B | 30.5B | 32.4B | 30.4B | 1.5B |
| Total Operating Expenses | 102.2B | 97.4B | 97.0B | 87.4B | 75.3B |
| Cost and Expenses | 242.1B | 223.3B | 208.3B | 183.0B | 164.8B |
| Operating Income (EBIT) | 17.6B | 8.3B | 2.6B | 9.6B | 12.6B |
| Non-Operating | |||||
| Interest Income | 2.9B | 3.5B | 4.6B | 2.8B | 2.1B |
| Interest Expense | 1.1B | 980.0M | 382.5M | 2.6B | 2.8B |
| Net Interest Income | 1.7B | 2.5B | 4.2B | 211.0M | (672.7M) |
| Other Non-Op Income/Expense | 12.1B | 4.2B | 8.4B | (14.1B) | (3.6B) |
| Non-Operating Income (excl Interest) | (4.5B) | (5.0B) | (8.8B) | 11.5B | 855.8M |
| EBT (Pre-Tax Income) | 29.7B | 12.5B | 11.0B | (4.5B) | 8.9B |
| Income Tax Expense | 4.2B | 487.7M | 16.1B | (271.0M) | 87.7M |
| Bottom Line | |||||
| Net Income | 17.8B | 5.3B | (10.9B) | (10.4B) | 5.8B |
| Earnings from Cont. Ops | 25.5B | 12.0B | (5.1B) | (4.2B) | 8.8B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 17.8B | 5.3B | (10.9B) | (10.4B) | 5.8B |
| Per Share | |||||
| Basic EPS | ₩763 | ₩226 | (₩474) | (₩463) | ₩265 |
| Diluted EPS | ₩763 | ₩226 | (₩474) | (₩456) | ₩265 |
| Revenue Per Share | ₩11,103 | ₩9,881 | ₩9,164 | ₩8,592 | ₩8,036 |
| Shares | |||||
| Basic Shares Outstanding | 23.4M | 23.5M | 23.0M | 22.4M | 22.1M |
| Diluted Shares Outstanding | 23.4M | 23.5M | 23.0M | 22.8M | 22.1M |
| Profitability Metrics | |||||
| EBITDA | 34.1B | 19.3B | 20.4B | 6.5B | 19.4B |
| D&A | 11.8B | 11.0B | 9.0B | 8.4B | 7.7B |
| EBIT | 20.1B | 8.3B | 11.4B | (1.9B) | 11.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026